Evotec

Just‑Evotec Biologics launches a Phase‑I study for the orthopox antibody cocktail JST‑018 under a U.S. Department of Defense program; together with a previous contract the potential order volume is up to USD 123.9 million. The project confirms the functionality of Evotec’s continuous‑manufacturing platform through production of clinical material and strengthens the high‑margin biologics division. Chart‑wise, Evotec’s share remains in an intact downtrend and is trading near its 52‑week low, so investors will still need patience and risk tolerance until operational successes are reflected in the group’s financials. » Więcej na finanzen.net

Evotec has started a research collaboration with Plectonic Biotech to investigate a new immunotherapy approach and the combination of the BiTco platform with LOGIBODY technology for the treatment of solid tumors. Financial details of the collaboration were not disclosed. Despite the news, Evotec's share briefly fell to a multi-year low of €3.13; there remains a lack of news to support a sustained trend reversal and confidence in the capital markets. » Więcej na deraktionaer.de

Evotec reports a 19.2% decline in revenue for H1/2026 to just over €300 million and an adjusted negative EBITDA of €42.7 million. Management attributes the weakness to delayed revenue recognition and lowers the full-year forecast, but expects a pickup in the fourth quarter from increased activity in discovery and preclinical development. To finance » Więcej na finanzen.net